Immunohistochemically detected IDH1 R132H mutation is rare and mostly heterogeneous in prostate cancer
作者: Andrea HinschMeta BrolundClaudia Hube-MaggMartina KluthRonald SimonChristina Möller-KoopGuido SauterStefan SteurerAndreas LuebkeAlexander AngererCorinna WittmerEmily NeubauerCosima GöbelFranziska BüscheckSarah MinnerWaldemar WilczakThorsten SchlommFrank JacobsenTill Sebastian ClauditzTill KrechMaria Christina TsourlakisCornelia Schroeder
作者单位: 1Institute of Pathology, University Medical Center Hamburg-Eppendorf
2General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf
3Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf
4Section for Translational Prostate Cancer Research, Department of Urology, University Medical Center Hamburg-Eppendorf
刊名: World Journal of Urology, 2018, Vol.36 (6), pp.877-882
来源数据库: Springer Nature Journal
DOI: 10.1007/s00345-018-2225-7
关键词: IDH1ERGDeletionProstate cancerTMA
英文摘要: Abstract(#br) Background(#br)IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy.(#br) Methods(#br)In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1 R132H mutation.(#br) Results(#br)IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade ( p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2 - ERG fusion as well as deletion of...
全文获取路径: Springer Nature  (合作)
影响因子:2.888 (2012)